Skip to main content
logo
AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
263.29
-2.99 (-1.12%)
At close: Sep 29, 2026, 4:00 PM EDT
264.10
+0.81 (0.31%)
Pre-market: Sep 30, 2026, 8:46 AM EDT

AbbVie Revenue by Segment

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
Immunology
32.59B31.43B30.41B29.07B28.24B27.58B26.68B26.34BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Immunology Growth
15.41%13.99%13.96%10.38%8.27%6.39%2.09%-2.83%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Neuroscience
11.91B11.36B10.77B10.32B9.84B9.32B9.00B8.58BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Neuroscience Growth
21.02%21.94%19.65%20.17%19.03%16.64%16.61%17.06%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Hematologic Oncology
6.63B6.65B6.66B6.68B6.69B6.65B6.56B6.37BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Hematologic Oncology Growth
-0.90%0.12%1.53%4.85%7.89%9.98%10.82%5.57%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Aesthetics
4.95B4.94B4.86B4.87B4.92B5.03B5.18B5.25BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Aesthetics Growth
0.59%-1.69%-6.11%-7.18%-6.31%-4.08%-2.23%0.75%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Other Products
3.82B3.92B3.74B3.76B3.63B3.56B3.65B3.70BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Other Products Growth
5.18%10.26%2.41%1.62%-4.24%-5.85%-4.15%-3.14%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Eye Care
1.09B1.60B2.11B2.18B2.19B2.21B2.24B2.18BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
Eye Care Growth
-50.30%-27.47%-5.93%-0.28%-3.10%-5.76%-7.16%-9.88%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Revenue by Geography

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019
United States
48.69B47.59B46.60B45.54B44.62B43.97B43.03B42.41BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
United States Growth
9.12%8.25%8.31%7.40%5.97%5.38%2.74%-1.30%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
International
15.69B15.23B14.56B14.10B13.71B13.40B13.31B13.13BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade
International Growth
14.51%13.63%9.41%7.41%6.31%5.68%7.00%7.85%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade

Operating Expense Breakdown

Period EndingJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022Mar 31, 2022Dec 31, 2021Sep 30, 2021Jun 30, 2021Mar 31, 2021Dec 31, 2020Sep 30, 2020Jun 30, 2020Mar 31, 2020Dec 31, 2019Sep 30, 2019Jun 30, 2019Mar 31, 2019Dec 31, 2018Sep 30, 2018Jun 30, 2018
Selling, General, and Administrative
14.67B14.30B14.01B13.97B14.61B14.73B14.75B14.09BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade--
Selling, General, and Administrative Growth
0.47%-2.95%-5.03%-0.85%10.18%12.03%14.61%7.59%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade--
Research and Development
9.71B9.50B9.10B13.29B13.10B12.92B12.79B7.94BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade--
Research and Development Growth
-25.86%-26.46%-28.89%67.31%73.84%76.44%66.66%5.39%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade--
Acquired In-Process R&D
4.98B5.51B5.02B5.33B2.73B2.84B2.76B1.47BUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade--
Acquired In-Process R&D Growth
82.62%94.02%81.94%263.48%88.20%258.71%254.37%98.24%UpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade--
Other Expenses
--434.00M-434.00M-48.00MUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgradeUpgrade